FLT3 and acute myeloid leukemia: Recent subgroup analyses of various phase 3 trials investigating targeted drugs alone or in combination with standard therapy in IDH1 or FLT3 mutant AML patients have shown sex-based OS differences, either favoring male or female patients [32].